Perseus Proteomics is Therapeutic antibody development targeting transferrin receptor for various blood cancer diseases and antibody drug discovery platform base on phage display. The company licensed out 2 product candidates and possesses 1 internal product candidate (PPMX-T003) for hematologic cancer (Polycythemia Vera) at Ph1 in Japan since 2019. PPMX-T003, targets a transferrin receptor (TfR) that is expressed on the cell membrane and regulates cellular iron uptake. The cellular iron uptake is essential for cell survival and proliferation. As TfR is highly expressed in many cancer cells, it is widely known that the inhibition of iron uptake depletes its levels within cells, leading to cell death. Many attempts to achieve inhibition of iron uptake have been made in the healthcare industry for a long time, but without success. Through the phage display method, the fully human antibody, PPMX-T003, which kills cancer cells effectively with its extremely potent inhibitory activity against iron uptake.
Aboleris Pharma is developing new immunomodulators for immune mediated diseases. The company has two programs: 1) a monoclonal antibody anti-CD45RC (ABIS-45RC) and 2) the cytokine IL-34 (ABIS-34).
Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.